BMS will shed Otezla to push Celgene takeover throughBristol-Myers Squibb has opted to divest big-selling psoriasis drug Otezla to smooth the passage of its $74 billion Share XBMS will shed Otezla to push Celgene takeover throughhttps://pharmaphorum.com/news/bms-will-shed-otezla-to-push-celgene-takeover-through/
Celgene gets MS blockbuster-in-waiting ozanimod back on trackRegulators in the US and EU have formally started their review of Celgene’s oral drug ozanimod for multiple Share XCelgene gets MS blockbuster-in-waiting ozanimod back on trackhttps://pharmaphorum.com/news/celgene-gets-ms-blockbuster-in-waiting-ozanimod-back-on-track/
BMS reveals its post-Celgene takeover management teamBristol-Myers Squibb has announced its new-look leadership after the Celgene takeover goes through, and it reveals a mixed Share XBMS reveals its post-Celgene takeover management teamhttps://pharmaphorum.com/news/bms-post-celgene-takeover-management-team/
Celgene gets speedy review for thalassaemia drug luspaterceptIt’s shaping up to be a landmark year for the community of patients with rare blood disorder beta Share XCelgene gets speedy review for thalassaemia drug luspatercepthttps://pharmaphorum.com/news/celgene-gets-speedy-review-for-thalassaemia-drug-luspatercept/
Celgene bags FDA okay for Revlimid combo in lymphomaCelgene has added another new indication for its blood cancer blockbuster Revlimid, with the FDA approving its use Share XCelgene bags FDA okay for Revlimid combo in lymphomahttps://pharmaphorum.com/news/celgene-bags-fda-okay-for-revlimid-combo-in-lymphoma/
Celgene files potential blockbuster luspaterceptCelgene and Acceleron Pharma have submitted their blood disorder drug luspatercept for approval with the FDA, setting up Share XCelgene files potential blockbuster luspatercepthttps://pharmaphorum.com/news/celgene-files-potential-blockbuster-luspatercept/
Celgene-BMS merger looks good to go as shareholder backs downBristol-Myers Squibb’s mega-merger with Celgene looks set to go ahead after activist hedge fund Starboard Value backed out Share XCelgene-BMS merger looks good to go as shareholder backs downhttps://pharmaphorum.com/news/celgene-bms-merger-looks-good-to-go-as-shareholder-backs-down/
MS drug market heats up as FDA backs Novartis’ new pillThe FDA has approved Novartis’ Mayzent (siponimod) multiple sclerosis pill for relapsing forms of the disease, dealing a Share XMS drug market heats up as FDA backs Novartis’ new pillhttps://pharmaphorum.com/news/ms-drug-market-heats-up-as-fda-backs-novartis-new-pill/
Celgene refiles potential MS blockbuster ozanimod with FDACelgene has filed its highly anticipated oral MS drug ozanimod with the US regulator, more than a year Share XCelgene refiles potential MS blockbuster ozanimod with FDAhttps://pharmaphorum.com/news/celgene-refiles-potential-ms-blockbuster-ozanimod-with-fda/
